Pulse Biosciences (NASDAQ:PLSE) Posts Earnings Results, Beats Expectations By $0.05 EPS

Pulse Biosciences (NASDAQ:PLSE) released its quarterly earnings data on Monday. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05, Zacks reports.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE traded up $0.41 during midday trading on Wednesday, hitting $19.06. 82,044 shares of the company’s stock traded hands, compared to its average volume of 311,822. The company has a market cap of $1.30 billion, a PE ratio of -17.38 and a beta of 1.63. The firm’s fifty day moving average price is $20.85 and its two-hundred day moving average price is $17.56. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $26.30.

Insider Transactions at Pulse Biosciences

In related news, insider Kevin Patrick Danahy sold 5,000 shares of Pulse Biosciences stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $23.64, for a total transaction of $118,200.00. Following the sale, the insider owned 43,298 shares of the company’s stock, valued at $1,023,564.72. The trade was a 10.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 85,000 shares of company stock worth $1,994,400. Insiders own 74.60% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. Jane Street Group LLC purchased a new position in Pulse Biosciences in the 1st quarter valued at about $323,000. Creative Planning boosted its position in Pulse Biosciences by 26.3% in the 2nd quarter. Creative Planning now owns 18,971 shares of the company’s stock valued at $286,000 after buying an additional 3,951 shares during the last quarter. Legal & General Group Plc boosted its position in Pulse Biosciences by 57.7% in the 2nd quarter. Legal & General Group Plc now owns 22,415 shares of the company’s stock valued at $338,000 after buying an additional 8,197 shares during the last quarter. Norges Bank purchased a new position in Pulse Biosciences in the 2nd quarter valued at about $302,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Pulse Biosciences in the 2nd quarter valued at about $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PLSE shares. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 20th. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $30.00.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.